Wednesday, December 31, 2025 12/31/2025

Characterize the metabolic landscape of ARID1A-mutated ovarian cancer

Award Number: R21CA287351
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/01/2024
PERIOD OF PERFORMANCE END DATE: 11/30/2026

Group Awards By:

View Award Description

Characterize the metabolic landscape of ARID1A-mutated ovarian cancer - Abstract Ovarian clear cell carcinoma (OCCC) is a rare and highly lethal gynecological cancer. The majority of OCCC patients carry inactivating mutations in ARID1A, a component of the SWI/SNF chromatin- remodeling complex, leading to a lack of response to standard chemotherapy and poor prognosis. To address this unmet medical need, recent research, including from our own laboratory, has suggested that targeting mitochondrial respiration may be a promising approach for treating ARID1A-mutated tumors. However, there is still a significant knowledge gap in understanding the specific mitochondrial Electron Transport Chain (mETC) components that contribute to the dependency of ARID1A-deficient cancer cells on mitochondrial respiration. Current mitochondrial inhibitors lack specificity and often cause severe side effects. This grant proposal aims to identify unique proteomic and functional mitochondrial signatures associated with ARID1A deficiency in OCCC tumors. Additionally, it seeks to perform a genetic screen of mETC drop-out in ARID1A-proficient and deficient cells. The results from this research could reveal potential therapeutic vulnerabilities within the mETC for ARID1A- deficient tumors, not only in OCCC but also in other cancers with ARID1A mutations. The innovative aspect of this grant lies in conducting a comprehensive analysis of mETC in ARID1A wild-type and mutated tumors and performing the first-ever mETC genetic screen in ARID1A-proficient and deficient cells. The findings from this research have the potential to uncover novel therapeutic targets for ARID1A-deficient OCCC tumors and may have broader implications for unresponsive tumors in different contexts.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $158,653 )
2026	2026	REGENTS OF THE UNIVERSITY OF MINNESOTA	2221 UNIVERSITY AVE SE STE 100	MINNEAPOLIS	MN	55414	HENNEPIN	USA	Cancer Treatment Research	000	2	12/8/2025	NON-COMPETING CONTINUATION	$158,653
														Subtotal = $158,653

Issue Date FY: 2025 ( Subtotal = $212,013 )
2025	2025	REGENTS OF THE UNIVERSITY OF MINNESOTA	200 OAK ST SE	MINNEAPOLIS	MN	55455	HENNEPIN	USA	Cancer Treatment Research	000	1	11/25/2024	NEW	$212,013
														Subtotal = $212,013

Grand Total All Awards = $370,666

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Characterize the metabolic landscape of ARID1A-mutated ovarian cancer

Award Number: R21CA287351

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/01/2024

PERIOD OF PERFORMANCE END DATE: 11/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer